• Inner Logic

  Participated · Seed · Jul 2026

  Inner Logic develops a simulation and data platform that allows device manufacturers to design, test, and validate procedural devices across thousands of virtual patients grounded in real clinical and procedural data. The company’s infrastructure aims to shift exploratory device development from physical prototypes and cadaver labs into in silico testing to accelerate iteration and broaden patient coverage. Founders include CEO Tito Porras, MD; CTO Mathias Unberath, PhD; and Chief Robotics Officer Axel Krieger, PhD, who collectively have authored over 400 peer-reviewed publications and are named inventors on more than 40 patents. Inner Logic has demonstrated its technology by training AI in simulation for orthopedic trauma and deploying it successfully on real hardware and patient anatomy, and by completing key steps of an autonomous gallbladder removal in a live animal model. The company is positioning its platform to support the development and validation of intelligent and autonomous procedural systems as they move toward clinical deployment. The announced financial position includes an $11.5 million seed round to advance product development and scaling.

• Infinity Bio

  Participated · Series A · Jun 2025

  Infinity Bio develops a proprietary MIPSA platform for unbiased, high-resolution analysis of the antibody reactome to reveal immune targets across viruses, human proteins, and allergens. Since founding in 2023 the company has built a 9,000 square-foot laboratory in Baltimore and developed core services including HuSIGHT™, VirSIGHT™, AllerSIGHT™, and MuSIGHT™. Its platform is capable of processing thousands of samples per week and serves academic, government, and biopharma customers. Infinity Bio recently acquired the assets of Serimmune, Inc., broadening its suite of antibody reactome services. The company plans to use investment proceeds to expand its commercial footprint, accelerate MIPSA development, and launch new immune profiling services. New MIPSA service offerings, including EnviroSIGHT™, are expected to launch in the second half of 2025.

• Pair Team

  Participated · Series A · Oct 2023

  Pair Team partners with local health centers and community-based organizations to provide virtual and community-integrated primary care, acting as an extension of partners to deliver clinical and mental health services. The company addresses social determinants of health such as housing, food, and transportation while connecting patients to care through a shared community health platform. Its platform leverages artificial intelligence to implement clinical best practices. Led by CEO Neil Batlivala, Pair Team works with safety net organizations to expand access to comprehensive care. The company plans to accelerate expansion across California, grow its network of partner organizations, and scale its team to support additional patients. Financial details in the article are limited to the recent Series A raise. Pair Team provides tech-enabled care teams and digital assistants that act as virtual extensions of community health centers to improve access and clinical outcomes for Medicaid and underserved populations. Its platform leverages AI to implement clinical best practices, integrate care with community-based organizations, and automate workflows so clinicians can focus on patients. The company addresses social and access barriers such as transportation, housing and food insecurity, and mobile phone access through a personalized, high-touch care experience. Pair Team reports that its solutions tripled annual wellness visit rates and increased clinic revenue by more than 40% in 2021; it manages care for thousands of Medicaid patients and has closed thousands of care gaps. Founded in 2019 by Neil Batlivala and Cassie Choi, Pair Team plans to expand nationally, grow its team, broaden partnerships with more clinics, and continue building next-generation care solutions for underserved communities. The new funding is intended to support hiring, partnerships, and continued product development to scale its operations platform and automation. Pair Team is an end-to-end operations platform for primary care, backed by the company’s own care team. For patients, Pair provides a comprehensive solution that covers the front, mid, and back-office. Its automation combined with a human-in-the-loop approach handles patient outreach, scheduling, e-forms, care gap reports, record requests, referrals, lab coordination and other administrative tasks to offload traditional front-desk and medical assistant duties. For practices, Pair monitors patient data and triggers automated workflows to ensure critical visits are scheduled and care gaps are addressed. The company was founded in 2019 by Neil Batlivala and Cassie Choi and is based in San Francisco, CA. Pair raised $2.7M in seed funding and intends to use the proceeds to expand operations and broaden its business reach.

• Scene Health

  Participated · Series B · Apr 2023

  Scene Health operates a video-based platform and mobile app that connects patients with a care team of pharmacists, nurses, and health coaches through daily video check-ins and in-app chat. Its tech-enabled solution combines video technology, clinical coaching, and validated interventions to improve medication administration, adherence, and address social determinants of health. Scene reports impacting more than 200,000 lives with over 40 million engagements and currently delivers programs for 720 customers across Medicaid and Medicare managed care organizations, public health departments, and life sciences organizations. The company cites evidence in 19 peer-reviewed publications demonstrating improved engagement, outcomes, and reduced costs. Recent validations include a CDC endorsement of video DOT for tuberculosis and a $1.67 million NIH grant to support pediatric heart transplant recipients. Scene has raised over $25 million in total funding since its 2014 founding.

• Delfi Diagnostics

  Participated · Series B · Jul 2022

  DELFI Diagnostics is a Palo Alto–based developer of blood-based cancer detection tests that use fragmentomics and advanced machine-learning methods applied to whole-genome sequencing data. The platform analyzes patterns of cell-free DNA fragments to detect chaotic signatures left by cancer cells. DELFI has commercialized FirstLook Lung, a blood test that evaluates DNA fragment patterns to indicate the presence of lung cancer. In an independent validation, FirstLook Lung demonstrated 80% sensitivity in a screening population, including early-stage detection, and a 99.8% negative predictive value. The company received an equity investment from the Merck Global Health Innovation Fund and intends to use the funds to accelerate development and commercialization of its cancer detection solutions. Led by CEO Susan Tousi, DELFI positions its fragmentomics and AI technologies as a potential high-precision, population-scale approach to early cancer detection at a disruptive price. Delfi Diagnostics has built a platform that analyzes cell-free DNA fragments across the entire genome using a proprietary, scalable whole-genome fragmentation approach. The platform is designed to enable a single, low-cost, and straightforward lab process for multiple liquid-biopsy tests and leverages machine learning to deliver high-performing results. Led by CEO and founder Victor Velculescu, the company is validating its technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG. Delfi is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring. The company intends to use the funds raised to continue development and commercialization of single-cancer early detection, multi-cancer early detection, and treatment-monitoring blood tests. Headquarters are listed in Palo Alto, CA and Baltimore, MD. Delfi Diagnostics is a Baltimore-based company developing a new class of high-performance, affordable liquid biopsy tests for early cancer detection. Its platform leverages machine learning and genome-wide fragmentation profiles of cell-free DNA to detect evidence of tumors from a blood sample and to pinpoint tumor location. The company is applying this platform to a range of products to detect specific cancers, such as lung cancer in at-risk individuals, and to identify multiple cancers in any individual. Delfi plans to use the funding to expand its team of cancer researchers and machine learning experts and to validate its next-generation liquid biopsy technology through multiple prospective clinical studies. Financially, Delfi raised $100M in a Series A financing led by OrbiMed. The company is led by founder and CEO Victor Velculescu.

No current team members are available.